Fostroxacitabine bralpamide
Peptideexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 5, 2018 (NCT03781934)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
CCC[C@H](C)OC(=O)[C@H](C)NP(=O)(OC[C@H]1OC[C@@H](n2ccc(N)nc2=O)O1)Oc1ccc(Br)cc1- Mol. weight
- 589.38 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL5314416 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03781934 | Phase 1/Phase 2 (Phase 2) | Sep 5, 2018 | Medivir, Northern Institute for Cancer Research Newcastle |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medivir | For profit | 1 | 1 | 1 | 2018 |
| Northern Institute for Cancer Research Newcastle | Academic/Hospital | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1